Is it necessary to gradually reduce the dosage of Vigabatrin/vigabatrin?

Vigabatrin/vigabatrin is an anti-epileptic drug that affects the central nervous system. The withdrawal process requires special caution. It is usually recommended to use a gradual reduction method, and sudden withdrawal is strictly prohibited. Its pharmacological effect is by inhibiting GABA transaminase, leading to an increase in GABA concentration in the brain. This mechanism allows the nervous system to adapt to the drug after long-term medication. Once it is suddenly interrupted, it may cause severe epilepsy recurrence or status epilepsy.

In clinical practice, the discontinuation of Vigabatrin is generally based on the following situations: first, the patient has been seizure-free for a long time, and slow withdrawal of the drug is considered; second, the patient develops severe retinal toxicity or visual field loss, and must be discontinued; third, the drug is ineffective or needs to be replaced with other anti-epileptic drugs. In either case, an individualized medication reduction plan needs to be developed under the guidance of a neurologist.

The standard dose reduction recommendation is to reduce the dose by 10% to 20% per week and gradually adjust it according to the patient's condition, seizure control, and whether other anti-epileptic drugs are combined. Usually, the entire medication reduction process may take several weeks to months. Especially for patients who have been taking medication for more than 6 months, it is not recommended to stop the entire dose within 1 week.

If a patient experiences a recurrence of epilepsy during the tapering process, doctors usually recommend returning to the last stable dose and reassessing whether it is appropriate to continue tapering. For patients taking concomitant medications, priority should be given to adjusting non-main drugs to avoid superposition of adverse reactions caused by simultaneous withdrawal of multiple drugs.

In addition, Vigabatrin may cause irreversible neurotoxicity such as visual field loss. Long-term users are advised to continue visual monitoring during the tapering period. Even after stopping the drug, some visual side effects may continue or progress. Therefore, the drug withdrawal process is not only a pharmacological issue, but also requires comprehensive clinical monitoring.

Reference materials:https://www.sabril.net/